Search

Etazolate

EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

MLN2222

MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

Bezisterim

Rexin G

Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. … It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.

EGEN-001

EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity

Efavaleukin alfa

Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker.

KB3305

KB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.

Aprobarbital

Aprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects. … A primary treatment indicated for the use of aprobarbital was subsequently insomnia.

TAK-475

TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.

GC-373

The results showed potent inhibition of the target, suggesting that GC-373 holds therapeutic potential for Covid-19[A219036]. … GC-373 has been shown to inhibit the M^pro target in various coronavirus strains, including feline, mink, and ferret M^pro [A219041].